|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's range||48.00 - 48.79|
|52-week range||39.72 - 51.05|
|Beta (5Y monthly)||0.29|
|PE ratio (TTM)||22.04|
|Forward dividend & yield||1.22 (2.50%)|
|Ex-dividend date||18 Mar 2021|
|1y target est||56.44|
Shares of the clinical-stage biotech Atea Pharmaceuticals (NASDAQ: AVIR) closed the week down by a whopping 68.6%, according to data from S&P Global Market Intelligence. The biotech's stock plummeted last Tuesday after announcing that its oral antiviral pill, known as AT-527, badly missed the mark in a phase 2 trial called MOONSONG for patients with mild or moderate cases of COVID-19. AT-527 is being co-developed with pharma heavyweight Roche (OTC: RHHBY).
SOUTH SAN FRANCISCO, Calif., October 22, 2021--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Susvimo™ (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of people with wet, or neovascular, age-related macular degeneration (AMD) who have previously responded to at least two anti-vascular endothelial growth factor (VEGF) injections. Wet AMD is a potentially
J&J (JNJ) beats estimates for earnings but misses the same for sales. FDA authorizes mix and match of COVID vaccine boosters.